ZA202101258B - Anti-mica/b antibodies that block mica/b shedding and methods of use - Google Patents
Anti-mica/b antibodies that block mica/b shedding and methods of useInfo
- Publication number
- ZA202101258B ZA202101258B ZA2021/01258A ZA202101258A ZA202101258B ZA 202101258 B ZA202101258 B ZA 202101258B ZA 2021/01258 A ZA2021/01258 A ZA 2021/01258A ZA 202101258 A ZA202101258 A ZA 202101258A ZA 202101258 B ZA202101258 B ZA 202101258B
- Authority
- ZA
- South Africa
- Prior art keywords
- mica
- antibodies
- methods
- shedding
- block
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862712608P | 2018-07-31 | 2018-07-31 | |
| PCT/US2019/044234 WO2020028428A2 (en) | 2018-07-31 | 2019-07-30 | Anti-mica/b antibodies that block mica/b shedding and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202101258B true ZA202101258B (en) | 2025-06-25 |
Family
ID=69231308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/01258A ZA202101258B (en) | 2018-07-31 | 2021-02-24 | Anti-mica/b antibodies that block mica/b shedding and methods of use |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12065493B2 (https=) |
| EP (1) | EP3830128A4 (https=) |
| JP (2) | JP7370376B2 (https=) |
| KR (1) | KR102832008B1 (https=) |
| CN (2) | CN119930819A (https=) |
| AU (1) | AU2019312565B2 (https=) |
| CA (1) | CA3108022A1 (https=) |
| IL (1) | IL280487B2 (https=) |
| MX (1) | MX2021001254A (https=) |
| MY (1) | MY207765A (https=) |
| PH (1) | PH12021550232A1 (https=) |
| SG (1) | SG11202100981TA (https=) |
| WO (1) | WO2020028428A2 (https=) |
| ZA (1) | ZA202101258B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021001254A (es) | 2018-07-31 | 2021-05-12 | Cullinan Mica Corp | Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso. |
| KR20230152783A (ko) | 2020-07-07 | 2023-11-03 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| CN115611982B (zh) * | 2021-07-14 | 2024-05-10 | 浙江大学 | 一种抗人MICA/Bα3区的单克隆抗体及其应用 |
| CN114369161B (zh) * | 2021-12-28 | 2023-06-23 | 合肥天港免疫药物有限公司 | Mica抗体及其应用 |
| CN114369162B (zh) * | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| US20250340651A1 (en) * | 2022-07-28 | 2025-11-06 | Cullinan Mica Corporation | Anti-mica/b antibodies with enhanced effector function and methods of use |
| CN118027195B (zh) | 2023-05-06 | 2025-07-04 | 合肥天港免疫药物有限公司 | 亲和力成熟的mica抗体及其应用 |
| CN119569886A (zh) | 2023-09-06 | 2025-03-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| WO2025085672A1 (en) * | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2483343A1 (en) | 2002-04-22 | 2003-10-30 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
| EP2289534B1 (en) | 2004-04-05 | 2017-08-30 | The Regents of The University of California | NKG2D antibodies for use in the treatment of rheumatoid arthritis or Crohn's disease |
| US8716195B2 (en) * | 2005-11-14 | 2014-05-06 | Bioren, Inc. | Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening |
| EP1857116A1 (en) | 2006-05-19 | 2007-11-21 | Novoplant GmbH | Antigen binding polypeptides against spike glycoprotein (S2) of bovine coronavirus |
| CA3011859A1 (en) | 2007-04-23 | 2008-10-30 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by erp5 |
| HUE034044T2 (en) | 2011-09-30 | 2018-01-29 | Dana Farber Cancer Inst Inc | Therapeutic peptides |
| AU2013218017B2 (en) * | 2012-02-07 | 2017-12-07 | Innate Pharma | MICA binding agents |
| US20150044224A1 (en) | 2012-03-02 | 2015-02-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Materials and methods for differential treatment of cancer |
| CA2896058A1 (en) * | 2012-12-24 | 2014-07-03 | Abbvie Inc. | Prolactin receptor binding proteins and uses thereof |
| WO2014140884A2 (en) | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Methods and devices for removal of immunosuppressive ligands |
| EP2970490A4 (en) | 2013-03-15 | 2017-04-26 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
| WO2014190914A1 (en) | 2013-05-30 | 2014-12-04 | The University Of Hong Kong | Materials and methods for treatment of liver cancer background of the invention |
| AU2015264114A1 (en) | 2014-05-21 | 2016-11-03 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer with anti BiP or anti MICA antibodies |
| EP3430047A1 (en) * | 2016-03-15 | 2019-01-23 | Innate Pharma | Anti-mica antibodies |
| WO2017209318A1 (ko) * | 2016-05-30 | 2017-12-07 | 다이노나(주) | 탄산탈수소화 효소에 결합하는 항체 및 이의 용도 |
| US11780924B2 (en) | 2016-06-21 | 2023-10-10 | University Of Oslo | HLA binding vaccine moieties and uses thereof |
| EP3293271A1 (en) | 2016-09-12 | 2018-03-14 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Marker and target as a diagnostic variable and target for therapy of metastatic cancer |
| CA3040421A1 (en) | 2016-10-19 | 2018-04-26 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
| WO2018081648A2 (en) | 2016-10-29 | 2018-05-03 | Genentech, Inc. | Anti-mic antibidies and methods of use |
| EP3577138A1 (en) | 2017-02-06 | 2019-12-11 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| CN112566659A (zh) | 2018-01-25 | 2021-03-26 | 库利南Mica公司 | Mica/b抗体和使用方法 |
| EP3768715A1 (en) | 2018-03-23 | 2021-01-27 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| EP3773676A4 (en) | 2018-04-03 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
| MX2021001254A (es) | 2018-07-31 | 2021-05-12 | Cullinan Mica Corp | Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso. |
| WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
-
2019
- 2019-07-30 MX MX2021001254A patent/MX2021001254A/es unknown
- 2019-07-30 SG SG11202100981TA patent/SG11202100981TA/en unknown
- 2019-07-30 EP EP19844652.8A patent/EP3830128A4/en active Pending
- 2019-07-30 JP JP2021505272A patent/JP7370376B2/ja active Active
- 2019-07-30 IL IL280487A patent/IL280487B2/en unknown
- 2019-07-30 MY MYPI2021000501A patent/MY207765A/en unknown
- 2019-07-30 CA CA3108022A patent/CA3108022A1/en active Pending
- 2019-07-30 AU AU2019312565A patent/AU2019312565B2/en active Active
- 2019-07-30 CN CN202510009976.3A patent/CN119930819A/zh active Pending
- 2019-07-30 KR KR1020217005972A patent/KR102832008B1/ko active Active
- 2019-07-30 WO PCT/US2019/044234 patent/WO2020028428A2/en not_active Ceased
- 2019-07-30 CN CN201980062628.5A patent/CN113056484B/zh active Active
-
2021
- 2021-01-29 US US17/162,585 patent/US12065493B2/en active Active
- 2021-01-29 PH PH12021550232A patent/PH12021550232A1/en unknown
- 2021-02-24 ZA ZA2021/01258A patent/ZA202101258B/en unknown
-
2023
- 2023-10-17 JP JP2023179043A patent/JP7734720B2/ja active Active
-
2024
- 2024-06-23 US US18/751,276 patent/US20250034262A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MY207765A (en) | 2025-03-17 |
| US20210253711A1 (en) | 2021-08-19 |
| AU2019312565A1 (en) | 2021-03-11 |
| JP2021532774A (ja) | 2021-12-02 |
| US20250034262A1 (en) | 2025-01-30 |
| WO2020028428A3 (en) | 2020-05-07 |
| SG11202100981TA (en) | 2021-02-25 |
| MX2021001254A (es) | 2021-05-12 |
| CN113056484A (zh) | 2021-06-29 |
| CA3108022A1 (en) | 2020-02-06 |
| US12065493B2 (en) | 2024-08-20 |
| CN113056484B (zh) | 2025-01-14 |
| IL280487B2 (en) | 2025-07-01 |
| BR112021001808A2 (pt) | 2021-08-03 |
| JP7370376B2 (ja) | 2023-10-27 |
| PH12021550232A1 (en) | 2021-12-06 |
| IL280487B1 (en) | 2025-03-01 |
| CN119930819A (zh) | 2025-05-06 |
| KR20210071947A (ko) | 2021-06-16 |
| EP3830128A2 (en) | 2021-06-09 |
| EP3830128A4 (en) | 2022-08-17 |
| IL280487A (en) | 2021-03-25 |
| AU2019312565B2 (en) | 2025-09-11 |
| WO2020028428A2 (en) | 2020-02-06 |
| JP2024009997A (ja) | 2024-01-23 |
| JP7734720B2 (ja) | 2025-09-05 |
| KR102832008B1 (ko) | 2025-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202101258B (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use | |
| WO2019147863A3 (en) | Mica/b antibodies and methods of use | |
| PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
| MX2016003593A (es) | Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico. | |
| PH12022551298A1 (en) | Antibodies specific for cd47, pd-l1, and uses thereof | |
| PH12019502282A1 (en) | Bispecific antibodies specifically binding to pd1 and lag3 | |
| AU2018366199A1 (en) | Bispecific and monospecific antibodies using novel anti-PD-1 sequences | |
| NZ732628A (en) | Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof | |
| PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| MA39266A (fr) | Anticorps bispécifiques anti cd3epsilon et bcma | |
| MX2019000730A (es) | Proteinas multiespecificas de union al antigeno y metodos de uso de estas. | |
| NZ779938A (en) | Bispecific antibodies specific for pd1 and tim3 | |
| NZ626269A (en) | Anti-phf-tau antibodies and their uses | |
| MX2015005719A (es) | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
| EA201992756A2 (ru) | Антитела против cd48 и их конъюгаты | |
| NZ724306A (en) | High affinity and aggregatively stable antibodies on the basis of variable domains vl and a derivative vhh | |
| MX2016008794A (es) | Secuencias de anticuerpos especificos para e. coli. | |
| MX2019011585A (es) | Anticuerpos miltiespecificos estables. | |
| JOP20220309A1 (ar) | أجسام مضادة تستهدف معقد يشتمل على hla-i ومولد ضد جديد غير تقليدية وطرق استخدامها | |
| MX2022015129A (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso. | |
| WO2016112078A3 (en) | Anti-phf-tau antibodies and their uses | |
| AU2016226097A8 (en) | scFv-Fc dimers that bind Transforming Growth Factor-Beta1 with high affinity, avidity and specificity | |
| EA201892096A1 (ru) | Нейтрализующие моноклональные антитела к il-25 и их применение | |
| EP3792279A3 (en) | Heavy chain only antibodies to ang-2 |